The substantial decrease in prostate cancer death rates since the mid 1990s thought to reflect improved treatment and the introduction and wide dissemination of Prostate Specific Antigen (PSA) blood test in men 50 or above since the late 1990s [20], [35], [36], [37]. This evidence concerns the gene KLK3 and Familial prostate cancer.